Other languages Circio Holding ASA

Equities

TRVX

NO0013033795

Real-time Oslo Bors Other stock markets 05:30:30 2024-04-30 am EDT			5-day change	1st Jan Change
2.43 ^NOK	+1.25%		-9.33%	-66.25%

Apr. 25	Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 17	Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus	Apr. 17
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment	Apr. 17
Circio Partner Exercises Option to License Cancer Vaccine in China	Mar. 19
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China	Mar. 19
Atlas Special Opportunities Converts Circio's Convertible Bonds to Shares	Feb. 05
Circio Doses First Patient in Phase 2 Trial of Cancer Vaccine	Feb. 01
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University	Feb. 01
Circio Gets Approval for EUR6 Million Loans Waiver for Tumor Cell Technology Development	Jan. 18
Atlas Special Opportunities Converts NOK1 Million of Circio Convertible Bonds	Jan. 10
Circio Partner Files Investigational New Drug Application for Cancer Vaccine in China	Dec. 12
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration	Dec. 12
Circio to Begin Clinical Trial for Blood Cancer Vaccine After Successful Safety Review	Dec. 07
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital	Dec. 07
Circio Joins Collaboration to Test the Combination of TG01 Vaccination with Daratumumab and Nivolumab in Immunotherapy-Resistant Patients with Mutant RAS Cancers	Nov. 16
Georgetown University-led Collaboration to Test Circio's Drug Candidate Against RAS-mutated Cancers	Nov. 16
Circio Holding ASA Announces Management Changes	23-10-18
Circio Holding ASA and Neoregen Biotech Enter Collaboration for Delivery of Novel Circular Rna Therapeutics Using Nict Technology	23-10-10
Circio Holding Asa Announces Oncos-102 Mesothelioma Study Published in Journal for Immunotherapy of Cancer	23-09-03
Circio Holding ASA Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Circio Holding ASA

Equities

TRVX

NO0013033795

Other languages

Filters